Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafenoquine in hospitalized babesiosis
NCT06207370Phase 2Recruiting
- Sponsor
- 60 Degrees Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Mar 2027
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tafenoquine in babesiosis, sponsored by 60 Degrees Pharmaceuticals. Started Jun 2024; status: recruiting.
02
Drugs
tafenoquine
03
Conditions
babesiosis
Beyond the preview
Go deeper on NCT06207370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207370.